GSK3: A possible link between beta amyloid peptide and tau protein

Experimental Neurology

Volumn 223, Issue 2, 2010, Pages 322-325

  Hernández, Félix ^a   Gómez de Barreda, Elena ^a   Fuster Matanzo, Almudena ^a   Lucas, José J ^a,b   Avila, Jesús ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer disease; ApoE4; Beta amyloid peptide; GSK3; Presenilin; Tau

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GLYCOGEN SYNTHASE KINASE 3; TAU PROTEIN;

ALZHEIMER DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PHOSPHORYLATION; TAU PROTEINS;

EID: 77952546195     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.09.011     Document Type: Review

References (63)

1. Alonso A.D., Grundke-Iqbal I., Barra H.S., Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:298-303.
2. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 1999, 453:260-264.
3. Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. Zbl. ges. Neuroñ. Psych. 1911, 4:356-385.
4. Avila J., Lucas J.J., Perez M., Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 2004, 84:361-384.
5. Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., Robakis N.K. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 2004, 23:2586-2596.
6. Brandt R., Hundelt M., Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta 2005, 1739:331-354.
7. Busciglio J., Lorenzo A., Yeh J., Yankner B.A. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995, 14:879-888.
8. Cardozo C., Michaud C. Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway. Arch. Biochem. Biophys. 2002, 408:103-110.
9. Carrettiero D.C., Hernandez I., Neveu P., Papagiannakopoulos T., Kosik K.S. The cochaperone BAG2 sweeps paired helical filament-insoluble tau from the microtubule. J. Neurosci. 2009, 29:2151-2161.
10. Caruso A., Motolese M., Iacovelli L., Caraci F., Copani A., Nicoletti F., Terstappen G.C., Gaviraghi G., Caricasole A. Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J. Neurochem. 2006, 98:364-371.
11. Cedazo-Minguez A., Popescu B.O., Blanco-Millan J.M., Akterin S., Pei J.J., Winblad B., Cowburn R.F. Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. J. Neurochem. 2003, 87:1152-1164.
12. Cselenyi C.S., Jernigan K.K., Tahinci E., Thorne C.A., Lee L.A., Lee E. LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3′s phosphorylation of beta-catenin. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8032-8037.
13. Ding H., Matthews T.A., Johnson G.V. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J. Biol. Chem. 2006, 281:19107-19114.
14. Drubin D.G., Kirschner M.W. Tau protein function in living cells. J. Cell Biol. 1986, 103:2739-2746.
15. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 1998, 143:777-794.
16. Engel T., Hernandez F., Avila J., Lucas J.J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 2006, 26:5083-5090.
17. Engel T., Lucas J.J., Gomez-Ramos P., Moran M.A., Avila J., Hernandez F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging 2006, 27:1258-1268.
18. Gems D., Partridge L. Insulin/IGF signalling and ageing: seeing the bigger picture. Curr. Opin. Genet. Dev. 2001, 11:287-292.
19. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122:1131-1135.
20. Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y.C., Zaidi M.S., Wisniewski H.M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261:6084-6089.
21. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4913-4917.
22. Guarente L., Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature 2000, 408:255-262.
23. Hanger D.P., Anderton B.H., Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 2009, 15:112-119.
24. Hernandez F., Nido J.D., Avila J., Villanueva N. GSK3 Inhibitors and Disease. Mini Rev. Med. Chem. 2009, 9:1024-1029.
25. Ishiguro K., Shiratsuchi A., Sato S., Omori A., Arioka M., Kobayashi S., Uchida T., Imahori K. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 1993, 325:167-172.
26. Jackson G.R., Wiedau-Pazos M., Sang T.K., Wagle N., Brown C.A., Massachi S., Geschwind D.H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002, 34:509-519.
27. Jicha G.A., Berenfeld B., Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J. Neurosci. Res. 1999, 55:713-723.
28. Johnson G.V., Jope R.S., Binder L.I. Proteolysis of tau by calpain. Biochem. Biophys. Res. Commun. 1989, 163:1505-1511.
29. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
30. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
31. Lee H.G., Perry G., Moreira P.I., Garrett M.R., Liu Q., Zhu X., Takeda A., Nunomura A., Smith M.A. Tau phosphorylation in Alzheimer's disease: pathogen or protector?. Trends Mol. Med. 2005, 11:164-169.
32. Lee H.K., Kumar P., Fu Q., Rosen K.M., Querfurth H.W. The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol. Biol. Cell 2009, 20:1533-1544.
33. Lim F., Hernandez F., Lucas J.J., Gomez-Ramos P., Moran M.A., Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell Neurosci. 2001, 18:702-714.
34. Linseman D.A., Butts B.D., Precht T.A., Phelps R.A., Le S.S., Laessig T.A., Bouchard R.J., Florez-McClure M.L., Heidenreich K.A. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J. Neurosci. 2004, 24:9993-10002.
35. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001, 20:27-39.
36. Magdesian M.H., Carvalho M.M., Mendes F.A., Saraiva L.M., Juliano M.A., Juliano L., Garcia-Abreu J., Ferreira S.T. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J. Biol. Chem. 2008, 283:9359-9368.
37. Martinez A., Perez D.I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. J. Alzheimers Dis. 2008, 15:181-191.
38. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:4245-4249.
39. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Titani K., Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 1993, 10:1151-1160.
40. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 1995, 270:823-829.
41. Morsch R., Simon W., Coleman P.D. Neurons may live for decades with neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 1999, 58:188-197.
42. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:6990-6995.
43. Perez M., Hernandez F., Gomez-Ramos A., Smith M., Perry G., Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur. J. Biochem. 2002, 269:1484-1489.
44. Perez M., Hernandez F., Lim F., Diaz-Nido J., Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. 2003, 5:301-308.
45. Perez M., Rojo A.I., Wandosell F., Diaz-Nido J., Avila J. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem. J. 2003, 372:129-136.
46. Perez M., Santa-Maria I., Tortosa E., Cuadros R., Del Valle M., Hernandez F., Moreno F.J., Avila J. The role of the VQIVYK peptide in tau protein phosphorylation. J. Neurochem. 2007, 103:1447-1460.
47. Perez M., Valpuesta J.M., Medina M., Montejo de Garcini E., Avila J. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J. Neurochem. 1996, 67:1183-1190.
48. Petrucelli L., Dickson D., Kehoe K., Taylor J., Snyder H., Grover A., De Lucia M., McGowan E., Lewis J., Prihar G., Kim J., Dillmann W.H., Browne S.E., Hall A., Voellmy R., Tsuboi Y., Dawson T.M., Wolozin B., Hardy J., Hutton M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 2004, 13:703-714.
49. Planel E., Miyasaka T., Launey T., Chui D.H., Tanemura K., Sato S., Murayama O., Ishiguro K., Tatebayashi Y., Takashima A. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J. Neurosci. 2004, 24:2401-2411.
50. Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 1998, 21:479-505.
51. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6364-6369.
52. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
53. Santa-Maria I., Hernandez F., Martin C.P., Avila J., Moreno F.J. Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. Biochemistry 2004, 43:2888-2897.
54. Schaffer B.A., Bertram L., Miller B.L., Mullin K., Weintraub S., Johnson N., Bigio E.H., Mesulam M., Wiedau-Pazos M., Jackson G.R., Cummings J.L., Cantor R.M., Levey A.I., Tanzi R.E., Geschwind D.H. Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch. Neurol. 2008, 65:1368-1374.
55. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
56. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1977-1981.
57. Takashima A., Murayama M., Murayama O., Kohno T., Honda T., Yasutake K., Nihonmatsu N., Mercken M., Yamaguchi H., Sugihara S., Wolozin B. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9637-9641.
58. Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., Hess F., Saint-Jeannet J.P., He X. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000, 407:530-535.
59. Townsend M., Mehta T., Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282:33305-33312.
60. von Bergen M., Friedhoff P., Biernat J., Heberle J., Mandelkow E.M., Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5129-5134.
61. Wang J.Z., Gong C.X., Zaidi T., Grundke-Iqbal I., Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and-2B. J. Biol. Chem. 1995, 270:4854-4860.
62. Weingarten M.D., Lockwood A.H., Hwo S.Y., Kirschner M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:1858-1862.
63. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9:2431-2438.